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ABSTRACT
Objectives: We evaluated the efficacy and safety of dalbavancin in ABSSSI and ‘other sites’ infections’ 
(OTA).
Methods: Observational study involving 11 Italian hospitals including patients that received ≥1 dose of 
dalbavancin in 2016–2019. The outcome was end-of-treatment efficacy and safety in ABSSSI and OTA in 
a real-life setting.
Results: 206 patients enrolled (males 50%, median age 62 [IQR 50–76] years), 60.2% ABSSSI, 39.8% OTA. 
69.7% ABSSSI vs 90.7% OTA (p = 0.003) and 46.3% ABSSSI vs 37.2% OTA (p = 0.786) received previous 
and concomitant antibiotics, respectively. 82.5% reached clinical cure . Eleven (5.4%) patients had non- 
serious adverse events (AE). OTA patients showed longer hospitalization (13.5 days, 5.5–22 vs 3, 0–11.7; 
p<0.0001) and received longer previous (18 days, 9–30 vs 11, 7–19; p = 0.007)/concomitant antibiotic 
treatments (21 days, 14–52 vs 11, 8–14; p < 0.0001), compared to ABSSSI. ABSSSI and OTA showed 
similar efficacy (85.5% vs 75%, p = 0.459) and safety (no AE: 81.5% vs 64.3%, p = 0.258); efficacy was 
independent of previous/concomitant therapies.
Conclusions: Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI 
and off-label indications. The preferential use of dalbavancin as second-line or combination therapy 
would seem to suggest the need for in-depth studies focused on its off-label use.
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1.1. Dalbavancin for the treatment of acute bacterial 
skin and skin-structure infections and other ‘difficult-to- 
treat infections’
Dalbavancin is a lipoglycopeptide antibiotic with unique phar-
macokinetic features. It demonstrated potent activity against 
several gram-positive bacteria, including methicillin-resistant 
Staphylococcus aureus (MRSA) [1].
Dalbavancin is approved for the treatment of ABSSSI [2], 
but it stands as an interesting option for ‘difficult-to-treat 
infections’ caused by susceptible gram-positive microorgan-
isms due to its half-life of 14.4 days, high bone penetration 
[3–6] and optimal safety [4,7–9].
Only one dose of dalbavancin is needed for ABSSSI [10]. 
Off-label use in ‘difficult-to-treat infections’ is an option for 
outpatient parenteral antimicrobial therapy (OPAT) that 
could reduce the need for hospitalization [11]. Studies 
about dalbavancin use in endocarditis and osteomyelitis 
[12–17] have been recently published, showing contrasting 
results. Interestingly, retrospective data show a high success 
rate with ≥2 doses of dalbavancin in bone infections [13], 
and a recent randomized clinical trial confirmed that two 
1500 mg weekly doses were effective as standard care in 
osteomyelitis [15]. Likewise, in a retrospective study, dalba-
vancin has proven high success rate as OPAT in 27 patients 
with endocarditis, even if only used after clearance of blood 
cultures and with another antimicrobial agent [14]; conver-
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sely, the emergence of glycopeptide/lipoglycopeptide non- 
susceptible S. aureus strains has been reported in small case 
series with unfavorable outcome [18–20].
1.2. Dalbavancin efficacy and safety in real-life settings
While dalbavancin efficacy and safety for ABSSSI have been 
demonstrated by clinical trials [5,6,8,10,19,20], we still miss data 
from real-life settings in Italy [16,21,22], where the prevalence of 
MRSA is one of the five highest in Europe (33.9%) [23] and an 
appropriate empirical therapeutic approach is crucial.
We hereby conducted an observational multicentric study 
aimed to evaluate the end-of-treatment efficacy and safety of 
dalbavancin in ABSSSI and other sites’ infections (OTA) in 
a real-life setting in Italy. We besides explored previous and 
concomitant antimicrobial treatments.
2. Methods
2.1. Study design and population
This is a retrospective observational study in 11 hospitals (8 
Italian cities), approved by the local Ethic Committees. We 
included patients ≥18 years treated with ≥1 dalbavancin 
dose (01/05/2016-30/06/2019). Patients were excluded if clin-
ical information was not available.
2.2. Study procedures
The following data were collected reviewing patients’ clinical 
records through an electronic case report form: demographics, 
comorbidities, Charlson comorbidity index (CCI), baseline and 
end-of-treatment (EOT) blood tests, type of infection (ABSSSI 
and OTA), community- or hospital-acquired infection and iso-
lated pathogens, prior/concomitant antimicrobial therapies, rea-
sons for dalbavancin use, dosages, length, clinical outcomes at 
EOT and during the follow-up, relapses, and adverse events (AEs).
Previous antibiotic treatments were antibiotics used before 
dalbavancin for the same infection; concomitant antibiotic 
treatments were antibiotics used in association with dalbavan-
cin. Among previous antibiotics, we collected monotherapies 
(the prescription of a single antibiotic before dalbavancin), 
combination therapies (the administration of two or more 
antibiotics before dalbavancin), and mixed mono-combo 
treatments (monotherapies and combination regimens that 
were sequentially prescribed before dalbavancin).
Reasons for dalbavancin use were indicated in clinical 
records, were reported by physicians who prescribed dalba-
vancin, and were study investigators or were obtained after 
chart review.
Follow-up was 30–180 days after the last dose of dalbavancin. 
Dosages were decided upon clinical evaluations. Microbiological 
tests were performed in each hospital according to their own 
policy.
2.3. Site of infections
The population was divided into patients with ABSSSI and OTA 
to evaluate in-label and off-label use of dalbavancin. ABSSSI 
was defined as a skin bacterial infection with a lesion size area 
of ≥75 cm2 [16]. OTA included osteomyelitis, prosthetic joint 
infections, endocarditis, septic arthritis, sepsis, central venous 
line (CVC)-related bloodstream infections (BSI), endovascular 
stent infections, relapsing staphylococcal furunculosis, cuta-
neous patch, or breast implant infections.
2.4. Primary and secondary outcome
The primary outcome was clinical cure as evaluated by physi-
cians at EOT defined as improvement of lesions and resolution 
of signs and symptoms of infection [16]. Failure was defined as 
persistent signs/symptoms, discontinuation for toxicity, or 
death. Relapse of signs/symptoms of infection within 7 days 
after EOT was also recorded. Dalbavancin efficacy was also 
recorded during the follow-up visit. Secondary outcomes were: 
i) safety and tolerability; ii) comparison between ABSSSI and 
OTA; iii) comparison between patients with or without pre-
vious/concomitant antibiotics. AEs were considered as indicated 
by the WHO (20), tolerability was defined as not discontinuation 
for toxicity and prevalence of AEs <20%.
2.5. Statistical analysis
Categorical variables were presented as absolute numbers, 
percentages, while continuous variables as median, inter-
quartile range. The percentage of patients who reached 
clinical cure, as previously defined, at EOT (efficacy) and 
the proportion of subjects who experienced an AE (safety) 
were compared between ABSSSI and OTA by Pearson’s 
Chi-square test. Differences between ABSSSI and OTA 
and according to the use of previous/concomitant anti-
biotics were explored by Pearson’s Chi-square/Fisher’s 
exact test or Mann–Whitney test. Logistic regression ana-
lyses were used to investigate whether previous (model 1) 
and concomitant antibiotics (model 2) were associated 
with clinical cure, adjusting for age, comorbidities, and 
infection’s site. Statistical analyses were performed with 
SPSS software.
3. Results
We enrolled 206 patients treated with ≥1 dose of dalbavancin: 
124 (60.2%) ABSSSI, 82 (39.8%) OTA.
3.1. Patients’ demographics and baseline characteristics
Characteristics of the study population are shown in Table1(a). 
The median age was 62 (IQR 50–76) years. 140/206 (68%) 
patients presented ≥1 comorbidity. The most common comor-
bidity was cardiovascular disease (72, 35%), followed by dia-
betes (43, 29.9%) (supplementary Figure 1). Despite no 
difference in the prevalence of comorbidities, ABSSSI had 
lower median CCI (p = 0.002) and less frequently cirrhosis 
(p = 0.005). Furthermore, ABSSSI were characterized by higher 
White Blood Cell (WBC) count (p = 0.015) and C-reactive 
protein (CRP), compared to OTA (p = 0.009) (Table1(a)).
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3.2. Infections and microorganisms
OTA included bone infections (29, 14.1% in detail: osteomye-
litis 25/29, 86% – spondylodiscitis 4/29, 14%), prosthetic joint 
infections (17, 8.3%), endocarditis (6, 2.9%), septic arthritis (4, 
1.9%), CVC-related BSI (4, 1.9%), sepsis (1, 0.5%), other infec-
tions (21, 10.2%).
Most infections were community-acquired with a higher 
proportion in ABSSSI (104/121, 85.9%) than in OTA (44/74, 
59.5% – unknown data for 3/124, 2.4% ABSSSI, and 8/82, 9% 
OTA; p < 0.0001).
Microbiological isolations are listed in Figure 1(a–c). Overall, 
128/206, 62% patients had no microbiological isolation (no 
cultural examination in 122 and negative culture in 6 subjects); 
the most frequent were MRSA (25/78, 32%), coagulase- 
negative Staphylococci (CoNS, 23/78, 29%) and methicillin- 
susceptible S. aureus (MSSA, 14/78, 18%).
In ABSSSI no microbiological isolation was available in the 
majority of patients (101/124, 81.4%); MRSA was the most 
represented pathogen (9/23, 39%).
The proportion of microbiological isolation was higher in 
OTA (no isolation only in 27/82, 33%) (p < 0.0001), and the 
most frequent microorganisms were CoNS (19/55, 35%), MRSA 
(16/55, 29%), and MSSA (10/55, 17%).
3.3. Use of dalbavancin
Data on patients’ hospitalization are shown in Table1(b).
Most patients (119/206, 57.8%) were treated in outpatient 
services, mainly within ABSSSI (76/124, 61%), with no differ-
ences compared to OTA (p = 0.321). Accordingly, OTA under-
went longer hospitalization versus ABSSSI (p < 0.0001).
Dalbavancin was administered at a standard dosage 
(1500 mg in single dose in 124/206, 60.2% patients, with no 
difference between ABSSSI and OTA); the maximum number of 
weekly repetition was 7 in a patient with osteomyelitis. While 
dalbavancin was used mainly empirically in ABSSSI (98/124, 
79%), 58/82, 71% (p < 0.0001) of OTA patients received dalba-
vancin as a targeted therapy. In both ABSSSI and OTA, the most 
common reason to choose dalbavancin was an easier way of 
administration (116/206, 56.3%) and failure to previous antibio-
tics (62/206, 30.1%); other less common reasons were antimi-
crobial resistance to previous regimens in 2/206 (1%), allergy in 
8/206 (3.9%), poor compliance in 4/206 (1.9%), and other rea-
sons or missing data in 14/206 (6.8%) of patients.
3.4. Outcomes
Clinical cure was obtained in 170/206 (82.5%) patients with no 
significant differences between groups: 106/170 (85.5%) and 
63/170 (75%) in ABSSSI and OTA, respectively (Figure 2(a)).
In OTA, the success rate was >75% in all infections (Figure 2 
(b)), except in CVC-related BSI (50%), but the number of 
patients in this group was only 4. Interestingly, dalbavancin 
displayed a favorable clinical outcome in 26/29 (89.7%) bone 
infections (Figure 2(b)).
Previous or concomitant therapy did not affect EOT out-
come (Figure 2(c–d)): success rates, however, seem higher in 
absence of previous therapy in ABSSSI (93.9% vs 87.7%) and in 
presence of concomitant therapy in OTA (86.7% vs 77.4%), 
without reaching statistical significance.
By fitting two models of univariable and multivariable logistic 
regression, adjusted for age, comorbidities, and infection’s site, 
previous and concomitant antibiotics were not associated with 






Other sites’ infections (OTA), 
n = 82 p Values
(a) Demographic characteristics and blood exams
Age, median (IQR) 62 (50–76) 62 (47–73) 61 (54–78) 0.068
Gender (males), n (%) 103 (50) 62 (51) 40 (48) 0.886
At least one comorbidity, n (%) 140 (68) 81 (65.3) 59 (71.9) 0.293
Charlson comorbidity index, median (IQR) 3 (1–5) 3 (1–5) 4 (1–6) 0.022







GFR, ml/min, median (IQR) 89 (71.5–101.5) 91 (72–101.7) 86 (67–102) 0.453







SGOT, UI/L, median (IQR) 22 (15–35) 24 (17–40) 18 (13–31.5) 0.016
SGPT, UI/L, median (IQR) 22 (15–36) 25 (20–123) 18 (12–32) 0.052
CRP, mg/L, median (IQR) 57 (14–120) 81 (20–123) 18.8 (9–105) 0.009
(b) Patients’ hospitalization
Setting, n (%)  
Hospital admission  
Day hospital  















LOS, median (IQR) 7 (0–18) 3 (0–11.7) 13.5 (5.5–22) <0.0001
Department, n (%) 0.01
Surgery 9 (4.4) 1 (0.8) 8 (9)
Medicine 14 (6.8) 8 (6) 6 (7)
Infectious diseases 112 (54.4) 67 (55) 45 (54)
Other 11 (5.3) 3 (2) 8 (9)
Unknown 60 (29.1) 45 (36.2) 17 (21)
Quantitative data are presented as median (interquartile range) and categorical data as absolute numbers (percentages). Comparison between ABSSSI and OTA is 
by Mann–Whitney test or Chi-square/exact Fisher’s test, as appropriate. GFR: glomerular filtration rate; BMI: body mass index; WBC: white blood cell count; 
SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvic transaminase; CRP: C-reactive protein; LOS: length of hospital stay. 
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a higher probability of clinical cure (model 1 previous antibiotics: 
AOR 0.557 vs no previous therapies, 95%CI 0.151–2.061, 
p = 0.381; model 2 concomitant antibiotics: AOR 1.387 vs no 
concomitant therapies, 95%CI 0.523–3.677, p = 0.51).
A sensitivity analysis comparing outcome according to differ-
ent reasons of dalbavancin choice showed that dalbavancin use 
after other antibiotics’ failure was not associated with a different 
outcome, compared to other reasons of dalbavancin prescrip-
tion: clinical cure was obtained in 52/59, 88.1% patients with 
failure to previous antibiotics (missing data in 3 patients) and in 
108/123, 87.8% subjects with other dalbavancin prescription’s 
reasons (missing data in 21 patients), p = 0.949.
A small proportion of patients presented a clinical relapse: 
12/206 (5.8%) within 7 days and 27/206 (13.1%) 7 days after 
EOT with no differences between ABSSSI and OTA. Median 
follow-up was 80 (IQR 43–121) days; at the follow-up visit, 126/ 
155 (81.3%) patients recovered (Table 2).
3.5. Safety
An excellent tolerability profile of dalbavancin was confirmed 
in our study. AEs are listed in Table 2; 11/206 (5.4%) patients 
presented an AE. Only one patient had a serious dermatologic 
AE (Stevens–Johnson syndrome), all other AEs were nonser-
ious. The most common AEs were dermatologic reactions. 
Dalbavancin was discontinued due to AE in three patients: 
two for a gastrointestinal and one for a dermatologic side 
effect.
3.6. Previous and concomitant antibiotic therapies
Previous and concomitant antibiotics are shown in Table 3.
3.7. Previous antibiotics
Data on antibiotics used prior to dalbavancin were available in 
194/206 (94.2%) patients (119/124, 95.9% ABSSSI and 75/82, 
91.4% OTA, Table3(a)).
Patients with or without previous antibiotics did not differ 
in any baseline characteristics (data not shown). Overall, 151/ 
194 (77.8%) patients received prior antibiotics for a median 
length of 15 (IQR 8–25) days. OTA more frequently received 
previous antibiotics than ABSSSI (p = 0.003) and for a longer 
duration (p = 0.007).
75/151 (50%) were treated with a previous monotherapy: 
the most used antibiotics were aminopenicillin (35/75, 47%), 
followed by fluoroquinolones (FQs), lipopeptides (7/75, 9% 
each) and glycopeptides (6/75, 8%).
Among those who underwent previous combination ther-
apy (50/151, 33%), the most frequent regimens were penicillin 
plus FQs (6/50, 12%) and cephalosporin or carbapenem plus 
lipopeptide (3/50, 6%). Mixed regimens (previous monothera-
pies and combination regimens that were sequentially pre-
scribed) were used in 17/151 (11%) subjects.
Within ABSSSI, monotherapy (50/83, 60%; penicillin plus 
beta-lactamase inhibitors in 28/50, 56%) was more commonly 
used than combination therapy (26/83, 31%) [penicillin plus 
FQs or lipopeptide-based regimen (6/26, 23% each), glycopep-
tides (5/26, 19%)].
In OTA, 25/68 (36.7%) patients had a monotherapy, with 
similar regimens to those used in the study population, and 
24/68 (35.4%) received a combination therapy. Compared to 
ABSSSI, the proportion of patients that received a previous 
mixed regimen (both monotherapies and combination regi-
mens before dalbavancin) was higher in OTA (p = 0.001).
3.8. Concomitant antibiotics
Data about antibiotics used in association with dalbavancin 
were available in 172/206 (83.5%) patients (108/124, 87% 
Figure 1. Type of infections and microbiological isolations in study population.
Proportion of isolated microorganisms in the study population (a), ABSSSI (b), and other 
infections (c). No microbiological isolation; MRSA Methicillin-Resistant Staphylococcus 
Aureus; MSSA Methicillin-Sensitive Staphylococcus Aureus; ConS, Coagulase-negative sta-
phylococci; E faecalis, Enterococcus faecalis, E faecium, Enterococcus faecium. 
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ABSSSI and 64/82, 78% OTA; Table3(b)). Concomitant treat-
ment was used in 82/172 (47%) patients (50/108, 46.3% ABSSSI 
and 31/64, 37.2% OTA, p = 0.786). Patients with or without 
concomitant antibiotics did not differ in any baseline charac-
teristics (data not shown). While the proportion of concomi-
tant treatment was similar between ABSSSI and OTA 
(p = 0.786), OTA received concomitant antibiotics for a longer 
period (p < 0.0001).
In ABSSSI, a single antibiotic in association with dalbavan-
cin was more frequently used than the association of ≥2 
antibiotics (37/50, 74%) and FQs were used in 17/37 (46%) 
regimens.
In OTA, the proportion of a single antibiotic in association 
with dalbavancin was 20/31 (62.5%) and FQs were the most 
frequent antimicrobials (6/20, 30%), followed by rifampin and 
tetracycline (3/20, 15% each). The association of ≥2 antibiotics 
with dalbavancin was prescribed in 7/31 (21.9%) patients and 
always included FQs.
4. Discussion
In a multicenter real-life Italian setting, dalbavancin demonstrated: 
i) an overall success rate in the treatment of both ABSSSI and non- 
ABSSSI infections >80%, with an optimal safety profile; ii) 
a frequent use as in-patient treatment after previous lines of 
antibiotic and in associations with other antibiotics also in 
ABSSSI; iii) equal efficacy when used alone and as a combination/ 
sequential therapy.
Dalbavancin is the first long-acting anti-infective approved by 
FDA, that has been recently investigated with encouraging results 
for in- and off-label indications [13,14,16,17,22,24–32]; clinical trials 
on osteomyelitis and complicated BSI are still ongoing 
(NCT03091439-NCT03426761-NCT03148756-NCT02940730).
We hereby show results of an observational study including 
206 patients that to our knowledge is the largest real-life 
setting of dalbavancin. Our population had a wide range of 
age and more than half presented ≥1 comorbidity, well 
reflecting the variety of Gram-positive infections and the clin-
ical context.
4.1. Dalbavancin’s efficacy in ABSSSI and OTA
Dalbavancin demonstrated a success rate >80%, up to 85.5% in 
ABSSSI, comparable to clinical trials [10,19,33] and previous real- 
life studies [6,16,17,22,28,30,31,34], coupled to optimal safety 
and tolerability in both ABSSSI and OTA, better than other real- 
life studies [16,17].
In our study dalbavancin has been primarily used for ABSSSI; 
contrarily, other European retrospective studies reported the use 
of this antibiotic mainly in non-ABSSSI [16,17,22]. Our clinical cure 
Figure 2. Efficacy of dalbavancin at end of treatment according to groups of infections and according to previous and concomitant antibiotic treatment.
Proportion of patients with clinical cure (defined as recovery of signs and symptoms of infection) at end of treatment with dalbavancin according to ABSSSI and other site’s infections (a), 
the type of other infections (b), concomitant antibiotic therapies (c), and previous antibiotic treatments (d). Pearson’s Chi-square test for comparison. 
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rates in OTA are worse than data by Wunsch et al. (89% of clinical 
cure in osteomyelitis, prosthetic joint infections, and endocarditis) 
[22]: we achieved also a 83.3% success in endocarditis, lower than 
92.6% reported by Toboudic et al. [21]. Conversely, we confirmed 
positive outcomes in bone and prosthetic joint infections, prob-
ably reflecting the good bone concentrations and activity against 
biofilms that were reported by previous works [3,13,15,16,35–37]. 
Lastly, despite the small sample size, we show that 3/4 (75%) 
patients diagnosed with arthritis obtained the clinical cure, in 
line with encouraging previous PK studies [3].
4.2. Main dalbavancin’s reasons of use
Aside from clinical efficacy, our study provides a deeper 
insight into the mode of dalbavancin use in our setting. The 
main reason for dalbavancin use was easier administration; it 
is well known that dalbavancin prescription could improve 
patients’ compliance and avoid hospitalization [13,16,17]. 
However, despite most ABSSSI patients were treated in out-
patient services, nearly 40% were still hospitalized, with 
a median 3-day hospitalization, all possibly suggesting that 
despite the indisputable advantage of dalbavancin 
Table 2. Outcome and safety profile of dalbavancin.
Population ABSSSI Other sites’ infections (OTA)
p ValuesN = 206 N = 124 N = 82
Outcome (EOT) 0.459
Recovery 170 (82.5%) 106 (85.5%) 63 (75%)
Failure 25 (12.2%) 13 (10.5%) 12 (14.2%)
Unknown 11 (5.3%) 5 (4%) 9 (10.8%)
Relapse 0.907
No 128 (62.1%) 82 (66.2%) 45 (53.6%)
<7 days 12 (5.8%) 7 (5.6%) 5 (5.9%)
≥7 days 27 (13.1%) 17 (13.7%) 10 (11.9%)




Recovery 126 (61.2%) 83 (66.9%) 43 (52.5%)
Relapse with new hospitalization 12 (5.8%) 5 (4%) 7 (8.5%)
Relapse without hospitalization 17 (8.3%) 12 (10%) 5 (6.1%)
Unknown 51 (24.7%) 24 (19.3%) 27 (32.9%)
AE 0.258
No 155 (75.7%) 101 (81.5%) 54 (64.3%)
Nonserious 10 (4.9%) 5 (4%) 5 (5.9%)
Serious 1 (0.5%) 0 1 (1.2%)
Unknown 40 (18.9%) 18 (14.5%) 22 (28.6%)
Type of AE 0.369
Dermatologic 5 (2.4%) 2 (1.6%) 3 (3.7%)
Gastrointestinal 3 (1.4%) 1 (0.8%) 2 (2.5%)
Liver toxicity 1 (0.4%) 0 1 (1.2%)
Quantitative data are presented as median (interquartile range) and categorical data as absolute numbers (percentages). Comparison between ABSSSI and OTA is by 
Mann–Whitney test or Chi-square/exact Fisher’s test, as appropriate. EOT: end of treatment; AE: adverse events. 
Table 3. Previous and concomitant treatment characteristics.




Other sites’ infections (OTA), 
N = 75
p Values
Previous antibiotic therapies, n (%) 151/194 (77.8) 83/119 (69.7) 68/75 (90.7) 0.003Previous antibiotic therapies, n (%)
0.001Single antibiotic 75 (50) 50 (60) 25 (36.7)
Combination therapy 50 (33) 26 (31) 24 (35.4)
Mixed regimen 17 (11) 3 (4) 14 (20.6)
Unknown 9 (6) 4 (5) 5 (7.3)
Previous antibiotic therapy, n (%) <0.0001
Empirical therapy 86 (57) 65 (78.4) 21 (30.9)
Targeted therapy 45 (29.8) 7 (8.4) 38 (55.9)
Unknown 20 (13.2) 11 (13.2) 9 (13.2)
Days of previous antibiotic therapies, median (IQR) 15 (8–25) 11 (7–19) 18 (9–30) 0.007




Other sites’ infections (OTA), 
N = 64
p Values
Concomitant antibiotic therapy, n (%) 82/172 (47) 50/108 (46.3) 31/64 (37.2) 0.786
Days of concomitant antibiotic therapies, median (IQR) 14 (8.75–20.25) 11 (8–14) 21 (14–52) <0.0001
Quantitative data are presented as median (interquartile range) and categorical data as absolute numbers (percentages). Comparison between ABSSSI and OTA is by 
Mann–Whitney test or Pearson’s Chi-square/Fisher’s exact test, as appropriate. Mixed antibiotic therapies – previous regimens including both mono and 
combination therapy sequentially. (a) Previous antibiotic treatment – antibiotics used before dalbavancin for the same infection; (b) Concomitant antibiotic 
treatment – antibiotics used in association with dalbavancin. 
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pharmacokinetic, the clinical setting and/or physician 
approach often involve brief hospital admissions even in 
ABSSSI. A possible reason likely stems from Italian economic/ 
reimbursement policies and should be addressed in specifi-
cally designed studies [16,34,38–40].
4.3. Previous and concomitant antibiotic therapies
Intrigued by the finding that in about 30% of our cohort dalba-
vancin was used secondary to previous antibiotic failure, we 
investigated possible differences according to previous/combi-
nation therapies. Indeed, one strength of this study was the 
collection of all prior/concomitant antibiotics. Overall 80% of 
patients received previous therapies, with a significantly higher 
proportion of OTA, that also had a longer previous antibiotic 
therapy. While the use of previous antibiotics in OTA could be 
considered reasonable, a different reasoning could probably 
apply to ABSSSI. Indeed, up to 70%, ABSSSI received the pre-
vious antibiotic for a median of 11 days, in spite of dalbavancin 
specific approval for skin infections. Moreover, almost 50% of 
patients received dalbavancin together with other antibiotics. 
ABSSSI were receiving long concomitant therapies (median of 
11 days), mostly with FQs, that are not even included in ABSSSI 
guidelines [41]. Taken together, we could speculate that the 
high propensity to long previous/concomitant therapies in 
ABSSSI might unravel an enduring concerned attitude about 
the risk of relapsing infection, probably related to the residual 
erythema/edema in ABSSSI.
Interestingly, as a possible response to such concern, our 
data showed no significant clinical advantage when dalba-
vancin was used alone or with previous/concomitant 
therapies.
4.4. Limitations of the study
Some limitations should be acknowledged that include the 
study’s retrospective nature and the lack of uniform criteria in 
dalbavancin use and of a control group. Furthermore, the 
limited size of OTA limits the possibility to draw definitive 
conclusions in these settings. Likewise, data on clinical relapse 
and follow-up visits were available only in about 80% of the 
patients, therefore hampering the speculations on the long- 
term dalbavancin efficacy.
5. Conclusions
To the best of our knowledge, this is the largest retro-
spective nation-wide study on dalbavancin. Our data sug-
gest that dalbavancin use as first-line treatment should be 
implemented especially in ABSSSI, without any concomi-
tant treatment when possible, and as an outpatient or 
emergency department’s regimen in order to reduce hos-
pitalization rates and costs. In OTA, despite excellent avail-
able data for bone infections [15], more experience and 
efficacy studies on larger populations are needed, espe-
cially in prosthetic joint infections, endocarditis, and com-
plicated bacteremia where dalbavancin could really change 
the paradigm of maintenance therapy.
In conclusion, despite its well-established safety and effi-
cacy, an optimal location for dalbavancin still remains some-
how elusive in Italy. According to our data, dalbavancin is 
currently placed as second-line and/or association therapy 
also in ABSSSI, somehow thwarting its potency and favor-
able pharmacokinetic properties. Should dalbavancin effi-
cacy in difficult-to-treat infections be confirmed in 
randomized controlled trials, the current off-label use of 
dalbavancin could be enhanced at the advantage of 
patients’ and antimicrobial stewardship’s perspective.
6. Expert opinion
Dalbavancin is lipoglycopeptide antibiotic with a long half-life, 
and proved safe and efficacious in the treatment of both 
ABSSSI and other “difficult-to-treat infections” including osteo-
myelitis, prosthetic joint infections, endocarditis, septic arthri-
tis, CVC-related BSI.
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